Assessing Immunogenicity of Biosimilar Therapeutic Monoclonal Antibodies: Regulatory and Bioanalytical Considerations
- 20 February 2013
- journal article
- review article
- Published by Taylor & Francis in Bioanalysis
- Vol. 5 (5) , 561-574
Abstract
This article reflects on methodological limitations for interpretation of relative immunogenicity of biosimilar and reference therapeutic monoclonal antibodies, in emphasizing the relevance of correlation of bioanalytical signals with appropriate clinical end points, and the possible need for post-marketing observational studies to indicate the impact of detected differences in anti-drug antibody incidence and magnitude on sustainability of treatment benefit. Given the current uncertainty regarding the longer term clinical impact of undesirable immunogenicity for reference products, there can be no predefined margin for an acceptable difference based on incidence and magnitude of detected anti-drug antibodies. Any detected differences should be assessed in relation to clinical parameters; and the designation of biosimilarity made with reference to the similarity demonstrated in the directly comparative quality, nonclinical and clinical evaluations. Application of this 'totality of evidence' approach is illustrated for infliximab and adalimumab.Keywords
This publication has 48 references indexed in Scilit:
- Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralisationAnnals of the Rheumatic Diseases, 2013
- Comparison of long‐term clinical outcome with etanercept treatment and adalimumab treatment of rheumatoid arthritis with respect to immunogenicityArthritis & Rheumatism, 2012
- In support of the European Union biosimilar frameworkNature Biotechnology, 2012
- Safety, immunogenicity and efficacy of subcutaneous biosimilar epoetin-α (HX575) in non-dialysis patients with renal anemia: a multi-center, randomized, double-blind studyClinical Nephrology, 2012
- Tungsten-Induced Denaturation and Aggregation of Epoetin Alfa During Primary Packaging as a Cause of ImmunogenicityPharmaceutical Research, 2011
- Severe infusion reactions to infliximab: aetiology, immunogenicity and risk factors in patients with inflammatory bowel diseaseAlimentary Pharmacology & Therapeutics, 2011
- Is there a need for immunopharmacologic guidance of anti–tumor necrosis factor therapies?Arthritis & Rheumatism, 2011
- Are we ready for therapeutic drug monitoring of biologic therapeutics?Arthritis Research & Therapy, 2011
- Toward biosimilar monoclonal antibodiesNature Biotechnology, 2008
- A risk-based bioanalytical strategy for the assessment of antibody immune responses against biological drugsNature Biotechnology, 2007